Safety and Efficacy of Drug Combinations Against Schistosomiasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

650 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of MBD in combination with PZQ in the treatment of SCH and STH in children aged 1-15 years of age.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Drug Combinations Against Triple Infections

NCT01050517

Parasitic Diseases

COMPLETED NA

Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis

NCT02734186

Schistosomiasis

WITHDRAWN PHASE4

Safety and Efficacy of Drug Combinations Against Trichuris Trichiura

NCT01050452

Parasitic Diseases

COMPLETED NA

Schistosoma Mansoni Morbidity in Children Aged 1-5 Years

NCT01901484

Intestinal Schistosomiasis

COMPLETED PHASE2

Health Benefits of Repeated Treatment in Pediatric Schistosomiasis

NCT01424410

Schistosomiasis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parasitic Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

albendazole + praziquantel

Group Type PLACEBO_COMPARATOR

albendazole + praziquantel

Intervention Type DRUG

albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)

2

mebendazole + praziquantel

Group Type ACTIVE_COMPARATOR

mebendazole + praziquantel

Intervention Type DRUG

mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

albendazole + praziquantel

albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)

Intervention Type DRUG

mebendazole + praziquantel

mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Those with an age of 1-15 years of age
* Are infected with schistosomiasis and soil-transmitted helminthiasis
* Whose parent consent and who are willing to participate

Exclusion Criteria

* Those with acute and chronic diseases other than schistosomiasis and soil-transmitted helminthiasis
* Those with a history of any serious adverse drug reactions

Minimum Eligible Age

1 Year

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No